Japan
· Delayed Price · Currency is JPY KYORIN Pharmaceutical Company Description
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally.
The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug.
It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products.
In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies’ technologies and collection of information concerning clinical trial.
The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1923 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 2,042 |
| CEO | Yutaka Ogihara |
Contact Details
Address: 6, Kanda Surugadai 4-Chome Tokyo, 101-8311 Japan | |
| Phone | 81 3 3525 4711 |
| Website | kyorin-pharm.co.jp |
Stock Details
| Ticker Symbol | 4569 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3247090008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yutaka Ogihara | Chief Executive Officer |
| Yasuji Kurose | Chief Financial Officer |